Research Article
Imaging Diagnosis of Primary Liver Cancer Using Magnetic Resonance Dilated Weighted Imaging and the Treatment Effect of Sorafenib
Table 1
Evaluation criteria of RECIST1.1.
| Efficacy classification | Symptom descriptions |
| Progressive disease (PD) | The largest diameter and the lowest increase of the target lesion was ≥20% or the new lesion was found | Stable disease (SD) | The largest diameter and decrease in diameter of the target lesion did not reach PR or the enlargement diameter did not reach PD | Partial response (PR) | The largest diameter and decrease in diameter of the target lesion reached ≥30% and maintained for more than 4 weeks | Complete response (CR) | All target lesions disappeared, no new lesions appeared, and the tumor markers were normal and maintained for more than 4 weeks |
|
|
Note: PR+CR was ORR; total DCR was the value of SD+PR+CR.
|